首页> 外文OA文献 >Recruited brain tumor-derived mesenchymal stem cells contribute to brain tumor progression.
【2h】

Recruited brain tumor-derived mesenchymal stem cells contribute to brain tumor progression.

机译:招募的脑肿瘤来源的间充质干细胞有助于脑肿瘤进展。

摘要

The identity of the cells that contribute to brain tumor structure and progression remains unclear. Mesenchymal stem cells (MSCs) have recently been isolated from normal mouse brain. Here, we report the infiltration of MSC-like cells into the GL261 murine glioma model. These Brain Tumor derived Mesenchymal Stem Cells (BT-MSCs) are defined with the phenotype (Lin-Sca-1+CD9+CD44+CD166+/-) and have multipotent differentiation capacity. We show that the infiltration of BT-MSCs correlates to tumor progression; furthermore, BT-MSCs increased the proliferation rate of GL261 cells in vitro. For the first time, we report that the majority of GL261 cells expressed mesenchymal phenotype under both adherent and sphere culture conditions in vitro, and that the non-MSC population is non-tumorigenic in vivo. Although the GL261 cell line expressed mesenchymal phenotype markers in vitro, most BT-MSCs are recruited cells from host origin in both wild type GL261 inoculated into GFP-transgenic mice and GL261-GFP cells inoculated into wild type mice. We show the expression of chemokine receptors CXCR4 and CXCR6 on different recruited cell populations. In vivo, the GL261 cells change marker profile, and acquire a phenotype that is more similar to cells growing in sphere culture conditions. Finally, we identify a BT-MSC population in human glioblastoma that is CD44+CD9+CD166+ both in freshly isolated and culture-expanded cells. Our data indicate that cells with MSC-like phenotype infiltrate into the tumor stroma and play an important role in tumor cell growth in vitro and in vivo. Thus we suggest that targeting BT-MSCs could be a possible strategy for treating glioblastoma patients. Stem Cells 2013.
机译:尚不清楚导致脑肿瘤结构和进展的细胞的身份。间充质干细胞(MSCs)最近已从正常小鼠的大脑中分离出来。在这里,我们报告MSC样细胞浸入GL261小鼠神经胶质瘤模型。这些脑肿瘤来源的间充质干细胞(BT-MSC)具有表型(Lin-Sca-1 + CD9 + CD44 + CD166 +/-)并具有多能分化能力。我们表明BT-MSCs的浸润与肿瘤的进展有关。此外,BT-MSCs可提高GL261细胞的体外增殖速率。首次,我们报道大多数GL261细胞在体外和贴壁培养条件下均表达间充质表型,并且非MSC群体在体内没有致瘤性。尽管GL261细胞系在体外表达了间充质表型标记,但大多数BT-MSCs都是从宿主来源募集的细胞,接种到GFP转基因小鼠中的野生型GL261和接种到野生型小鼠中的GL261-GFP细胞中。我们显示趋化因子受体CXCR4和CXCR6在不同募集的细胞群体上的表达。在体内,GL261细胞会改变标记物谱,并获得与球培养条件下生长的细胞更相似的表型。最后,我们确定了人胶质母细胞瘤中的BT-MSC群体,在新鲜分离和培养扩增的细胞中均为CD44 + CD9 + CD166 +。我们的数据表明具有MSC样表型的细胞浸润到肿瘤基质中,在体外和体内肿瘤细胞生长中起重要作用。因此,我们建议靶向BT-MSCs可能是治疗胶质母细胞瘤患者的可能策略。干细胞,2013年。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号